Maraviroc in Patients With Moderate and Severe COVID-19
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without
significant side effects in its current use in patients with HIV. CCR5 antagonism prior to
the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid
depletion and may alter cell trafficking of inflammatory cells, both increasing viral control
capacity and dampening damage to lung tissue, respectively. This study seeks to establish
whether one week of treatment with Maraviroc, used at its approved dosage for HIV, is safe
and tolerable in patients with SARS-CoV-2.